COMPARATIVE SAFETY AND EFFICACY OF CLARITHROMYCIN AND AMPICILLIN IN THE TREATMENT OF OUT-PATIENTS WITH ACUTE BACTERIAL EXACERBATION OF CHRONIC-BRONCHITIS

In an open, randomized trial, adult non-hospitalized patients with acu te bacterial exacerbation of chronic bronchitis were treated with 500 mg clarithromycin twice daily (n = 53) or 500 mg ampicillin four times daily (n = 50). Causative pathogens included S. pneumoniae, M. catarr halis, H. influenzae, H. parainfluenzae and S. aureus. For clinically evaluable patients, successful outcome (cure or improvement) was noted for 53/53 (100%) clarithromycin-treated patients and 46/47 (98%) ampi cillin-treated patients. Clinically significant improvement in signs a nd symptoms was comparable between treatment groups. There was 100 % b acteriological eradication in both treatment groups. Eight patients (1 5 %) in the clarithromycin group and 10 patients (20 %) in the ampicil lin group reported adverse events, the majority of which were mild or moderate in severity; six events in each treatment group were digestiv e-system disorders. The new macrolide, clarithromycin, appears to be e ffective and well-tolerated in the treatment of acute exacerbation of chronic bronchitis.